Global Antiviral Drug Market Insights Forecasts to 2033.

• The Global Antiviral Drug Market Size was Valued at USD 58.84 Billion in 2023
• The Market Size is Growing at a CAGR of 3.10% from 2023 to 2033.
• The Worldwide Antiviral Drug Market Size is Expected to Reach USD 79.84 Billion by 2033
• Europe Market is expected to grow the fastest during the forecast period

The Global Antiviral Drug Market Size is Anticipated to Exceed USD 79.84 Billion by 2033, Growing at a CAGR of 3.10% from 2023 to 2033.

Market Overview

Antiviral medications are a group of pharmaceuticals used to treat viral diseases, including hepatitis, herpes, HIV, and influenza. Usually, these medications are given as vaccinations. Furthermore, the majority of these medications treat certain viral diseases, but a small number of them—known as broad-spectrum antiviral medications—are effective against a variety of viruses. Many flu medications and various antiviral medications that target a wide range of infectious diseases, such as hepatitis, herpes simplex virus (HSV) infection, cytomegalovirus (CMV) infection, influenza, coronavirus infection (COVID-19), and others, have been approved by regulatory bodies around the world in recent years. The antiviral agents have a mechanism of action that inhibits the synthesis of DNA and that prevent from replication. Some of the antiviral drug act as a protease enzyme and prevent them from cell division. Many pharmaceutical companies are developing antiviral therapies to prevent the spread of infectious viral diseases. The global antiviral drug market is driven by the rising healthcare expenditure for better health services and also contributes in the growth.  Additionally, the need for antiviral medications is growing due to the better evolution of drug research processes.

Report Coverage

This research report categorizes the market for the global antiviral drug market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global antiviral drug market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global antiviral drug market.

Driving Factors

The global antiviral drug market is driven by various factors, including the prevalence of viral diseases in global regions. The increase in the prevalence of various diseases is driving the global antiviral drug market. According to the World Health Organization, one type of viral disease called influenza accounts for billions of cases a year, of which 3–5 million are severe diseases. In addition, 290000 to 650000 deaths are caused by respiratory diseases. Moreover, a rise in the number of elderly people in the world has the greatest chance of getting affected by viral infections, which fuels the growth of the global antiviral drug market. Older people are more likely to get affected by the virus as they have less immunity power, which makes them more susceptible to the infection. According to the World Health Organization (WHO), the number of elderly people is increasing significantly compared to past years. The WHO states that the number of people aged 60 years and older will rise by 1 billion to 1.4 billion in 2022.

Restraining Factors

The increased cost of the antiviral drug is significantly hampering the patient, hospital, and global antiviral drug markets. This rise in cost is due to increased expenses for manufacturing, research, and development, as well as the cost of bringing the drug approval to market. According to WebMD, the cost of HIV virus treatment for a month is USD 1800–4500. Patients who are not able to afford this medication rely on worse health outcomes. Therefore, it is expected to retrain the global antiviral drug market.

Market Segmentation

The Global Antiviral Drug Market share is classified into drug class, distribution channel and application

• The protease inhibitor segment is expected to hold the largest share of the global antiviral drug market during the forecast period.   

Based on the drug class, the global antiviral drug market is divided into DNA polymerase inhibitors, protease inhibitors, reverse transcriptase inhibitors, neuraminidase inhibitors, and others. Among these, the protease inhibitor segment is expected to hold the largest share of the global antiviral drug market during the forecast period. Protease inhibitors are antiretroviral therapy (ART) drugs. They are widely used in the treatment of various viral diseases, such as HIV, hepatitis C, and COVID-19, as a primary treatment. Protease inhibitors as antiviral drug include the development of next-generation protease inhibitors with the improved potency and better pharmacokinetics with lower side effects.

• The hospital pharmacy segment is expected to grow at the fastest pace in the global antiviral drug market during the forecast period.    

Based on the distribution channel, the global antiviral drug market is divided into hospital pharmacy, and retail pharmacy. Among these, the hospital pharmacy segment is expected to hold the largest share of the global antiviral drug market during the forecast period. The market share increase is dominated by the hospital pharmacy category. The main reasons for the growth of the pharmacy sector are the government's assistance for viral infections through the establishment of government-aided hospital pharmacies and an enhanced network of important businesses.

• The HIV segment is expected to hold the greatest share of the global antiviral drug market during the forecast period.    

Based on the application, the global antiviral drug market is divided into influenza, HIV, hepatitis, herpes, and others. Among these, the HIV segment is expected to hold the largest share of the global antiviral drug market during the forecast period. Antiretroviral therapy (ART) is the collective term for antiviral medications used to treat HIV. In order to inhibit viral reproduction, lower the viral load, and delay the course of the illness, these drugs act on distinct phases of the HIV lifecycle. The introduction of newer, more effective antiviral treatments with better tolerability and convenience has been a trend in the market for HIV medications. A noteworthy development is the move toward single-tablet regimens (STRs), which streamline therapy and enhance adherence by combining many antiviral medications into a single tablet.

Regional Segment Analysis of the Global Antiviral Drug Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global antiviral drug market over the predicted timeframe.

North America is anticipated to hold the largest share of the global antiviral drug market over the predicted timeframe. This is attributed to the availability of important medications in the United States, the rise in the prevalence of diseases like HIV there, and the US FDA's approval of the introduction of successful treatments in North America.  Furthermore, according to the Centre of Diseases Control and Prevention the influenza is increasing in the North America. Also ongoing clinical trials are fueling region industrial expansion growth in the North America. This is because there are large pharmaceutical businesses in the United States and the government is providing more funds to support the introduction of safe and efficient antiviral medications in North America.

Europe is expected to grow at the fastest pace in the global antiviral market during the forecast period. The region is predicted to increase moderately throughout the course of the projection period, supported by massive expenditures in the creation of new medications and treatments. A number of countries' easy clearance processes and encouraging healthcare policies are also responsible for this industry expansion.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global antiviral along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• GlaxoSmithKline plc.
• Merck & Co., Inc.
• AbbVie Inc.
• Reddy's Laboratories Ltd.
• Hoffmann-La Roche AG
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Aurobindo Pharma Limited
• Cipla, Inc.
• Mylan N.V.
• Gilead Sciences
• PFIZER INC. 
• SIGA TECHNOLOGIES 
• F. HOFFMANN-LA ROCHE LTD.
• HETERO.
• Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In January 2022, Aurobindo Pharma launched the drug molnupiravir with brand name Monalflu for the use in treatment of the covid-19.

• In May 2022, in collaboration with Genes2Me Pvt. Ltd., Cipla Limited today announced the commercialization of the "RT-Direct" multiplex COVID-19 RT PCR Test kit in India. In an effort to introduce more cutting-edge and inventive solutions to the market, Cipla is expanding the range of diagnostics it offers.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Global Antiviral Drug Market based on the below-mentioned segments: 

Global Antiviral Drug Market, By Drug Class

• DNA Polymerase Inhibitor
• Protease Inhibitors
• Reverse Transcriptase Inhibitor
• Neuraminidase Inhibitors
• Others

Global Antiviral Drug Market, By Distribution channel

• Hospital Pharmacy
• Retail Pharmacy

Global Antiviral Drug Market, By Application

• Influenza
• HIV
• Hepatitis
• Herpes
• Others

Global Antiviral Drug Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa